Valuation: Insulet Corporation

Capitalization 14.11B 11.95B 11B 10.41B 19.29B 1,306B 19.63B 129B 50.51B 633B 52.93B 51.83B 2,231B P/E ratio 2026 *
32.3x
P/E ratio 2027 * 25.4x
Enterprise value 14.08B 11.93B 10.97B 10.39B 19.25B 1,303B 19.59B 129B 50.39B 632B 52.81B 51.71B 2,226B EV / Sales 2026 *
4.26x
EV / Sales 2027 * 3.5x
Free-Float
99.46%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day+1.12%
1 week+3.45%
Current month-2.91%
1 month-11.61%
3 months-29.19%
6 months-36.05%
Current year-28.32%
1 week 194.61
Extreme 194.61
205.95
1 month 194.61
Extreme 194.61
232.18
Current year 194.61
Extreme 194.61
299.8
1 year 194.61
Extreme 194.61
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 26.5
Extreme 26.5
354.88
Manager TitleAgeSince
Chief Executive Officer 55 2025-04-27
Director of Finance/CFO 53 2025-09-29
Compliance Officer 50 2022-11-30
Director TitleAgeSince
Chairman 61 2018-12-31
Director/Board Member 61 2015-07-26
Director/Board Member 59 2017-08-09
Change 5d. change 1-year change 3-years change Capi.($)
+1.12%+3.45%-17.45%-36.59% 14.11B
+1.40%-3.48%-26.09%-7.38% 169B
+0.63%-1.17%+4.35%+4.96% 111B
-3.35%-1.68%+87.79%+101.70% 61.53B
+1.61%+2.10%+14.24%+95.70% 63.72B
+2.40%+2.80%-20.22%-38.14% 45.14B
+1.49%+4.47% - - 38.67B
+4.49%-0.06%-6.69%-46.08% 24.69B
+2.65%+1.44%+1.60%+20.01% 22.14B
+3.57%+10.80%+0.83%-33.77% 21.67B
Average +1.78%+1.87%+4.26%+6.71% 57.09B
Weighted average by Cap. +1.52%-0.13%+2.11%+15.02%

Financials

2026 *2027 *
Net sales 3.3B 2.8B 2.57B 2.44B 4.52B 306B 4.6B 30.16B 11.82B 148B 12.39B 12.13B 522B 3.94B 3.34B 3.07B 2.9B 5.38B 364B 5.48B 35.94B 14.09B 177B 14.77B 14.46B 622B
Net income 442M 374M 344M 326M 604M 40.85B 614M 4.03B 1.58B 19.8B 1.66B 1.62B 69.8B 567M 480M 442M 418M 775M 52.44B 788M 5.17B 2.03B 25.42B 2.13B 2.08B 89.59B
Net Debt -31.86M -26.99M -24.83M -23.5M -43.56M -2.95B -44.32M -291M -114M -1.43B -120M -117M -5.04B -329M -279M -256M -243M -450M -30.43B -457M -3B -1.18B -14.75B -1.23B -1.21B -51.98B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
26-04-17 203.73 $ +1.12% 864,852
26-04-16 201.47 $ -0.51% 744,797
26-04-15 202.50 $ +0.50% 802,957
26-04-14 201.49 $ +1.86% 733,449
26-04-13 197.81 $ +0.45% 665,795
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
203.73USD
Average target price
333.30USD
Spread / Average Target
+63.60%

Quarterly revenue - Rate of surprise